Market Cap 407.98B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 24.34
Forward PE 21.59
Profit Margin 7.59%
Debt to Equity Ratio -26.45
Volume 2,347,900
Avg Vol 5,555,974
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 76%
Beta 0.36
Analysts Strong Sell
Price Target $245.84

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
Juhanialainen
Juhanialainen Dec. 31 at 10:02 AM
$SLS Hey $ABBV – let’s make it $80 per share and call it a day. Happy new year!
1 · Reply
1iquid
1iquid Dec. 31 at 7:15 AM
💎 Liquid® Live Actionable Trade Asset: $ABBV Contracts: $ABBV January 15, 2027 $230 Calls Scale in: $22.52- $27.52 Scale out: $87.56-$150.10 Profit Potential : 139% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 31 at 3:04 AM
Actionable Trade Alert for $ABBV: Market Context: $ABBV is currently trading at $229.74, showing strong momentum with an RSI of 64.54, indicating potential overbought conditions but still room for upward movement. The stock is above its 30-day MA of $227.95 and 50-day MA of $226.77, suggesting bullish sentiment. Directional Bias: The stock is trending upward, having recently approached its 60-day high of $239.29. This upward trajectory, combined with the RSI and moving averages, supports a bullish outlook. Trade Plan: - Suggested Entry: $230.00 - Stop Loss: $225.00 (risking $5.00) - Take Profit Targets: 1. $235.00 (Target 1: 2.17% ROI) 2. $240.00 (Target 2: 4.48% ROI) 3. $269.00 (Target 3: 17% ROI) This plan aims for a minimum of 17% ROI on the third target while maintaining a favorable risk-reward ratio. Monitor price action closely for adjustments. https://privateprofiteers.com
0 · Reply
GoodTidings
GoodTidings Dec. 30 at 11:38 PM
$SLS Can we say that ex Pfizer part of Sellas board puts $ABBV behind in case the BO war takes off... Is the time ticking for $ABBV or does board membership not have any influence on BO outcome?!!! 🤔🤔🤔
0 · Reply
rpc630
rpc630 Dec. 30 at 8:21 PM
$SLS $ABBV $BMY $RHHBY The Kennedy Woman probably was on this treatment. God rest her soul 🙏
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 30 at 8:16 PM
$SLS Daily Reminder: AZA+VEN the BAT - Best Available Treatment for SLS Phase 3 Control Arm Patients RECENTLY FAILED 3 Large Phase 3 Trials: VIALE-M FAILED in AML CR1 Maintenance VIALE-T FAILED in AML Post Stemcell Maintenance VERONA FAILED in MDS/AML Precursor - ALL FAILED DUE TO TOXicity Key Fact: $ABBV $BMY $RHHBY who own Azacitidine and Venetoclax - - these 3 Large A** Pharma, Know Right Now, Gps is wholly responsible for the Miraculous Survival of these Aml Second remission patients. They know precisely how their drugs perform - these are the 3 Likely to Be Bidding Now while SLS is Still Massively Undervalued. Ps. does everyone know, SLS a 14 FTE Drug Development co, eliminated the entire direct commercialization team in March of last year - ? the entire Pharma Industry Knows SLS is on the Block and the Clock is ticking.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 30 at 7:27 PM
$SLS $ABBV bought $IMGN for $10.1B based on ELAHERE achieving a MOS of 16.4 months for Platinum Resistant Ovarian Cancer Patients. - Gps + Keytruda $MRK Phase 2 Results are Better - 18.4 Months MOS in PR/OC. GPS + Keytruda achieved better MOS Results than than a drug bought for $10.1B. This is just One non-AML Market Comp for Gps - and worth 20x the Whole SLS market cap. Massive ROI Opportunity Investing in SLS right now, Opportunity of a Lifetime. https://www.fiercepharma.com/pharma/inside-abbvies-10b-immunogen-buyout-and-bidding-war-it-won
2 · Reply
Arunas1
Arunas1 Dec. 30 at 4:27 PM
Really nasty set ups right now $IWM $DIA $AMGN $ABBV $WING
0 · Reply
Arunas1
Arunas1 Dec. 30 at 4:12 PM
$ABBV & $AMGN
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 30 at 3:50 PM
$SLS Do the Math on the Total Addressable Market for Gps Immunotherapy and you will understand how true these words are. Gps will Set Records for patient uptake rates: 4x Survival Advantage - while maintaining near 100% QoL - No Toxicity, ease to administer, manufacture and Store, high margin, IP rights into 2035, FDA/ EU Orphan and Fast Track Designation, with Rare Pediatric Priority Review. An infinite Dosing Regime in the Maintenance setting, Years of COMPOUNDED REVENUE. 100,000 Patients in AML Remission Right Now +40,000 to 50,000 per year who'll be Eligible. Just in AML ... GPs in Combination with Keytruda $MRK Achieved Better Phase 2 Survival data (18.4MOS), than $IMGN Elahere (16.4MOS) Platinum Resistant End Stage ovarian cancer patients, $ABBV bought Elahere for $10.1B... Do the MATH... I've been here a while, sort through my posts.
0 · Reply
Latest News on ABBV
Best Dividend Kings: December 2025

Dec 28, 2025, 6:44 AM EST - 3 days ago

Best Dividend Kings: December 2025

ABM ABT ADM ADP AWR BDX BKH


Trump to announce new drug-pricing deals later today

Dec 19, 2025, 10:45 AM EST - 11 days ago

Trump to announce new drug-pricing deals later today

AMGN AZN BMY GILD LLY MRK NVO


AbbVie: Unique Mix Of Growth And Value

Dec 10, 2025, 8:01 PM EST - 20 days ago

AbbVie: Unique Mix Of Growth And Value


Best Dividend Aristocrats For December 2025

Nov 29, 2025, 8:02 AM EST - 4 weeks ago

Best Dividend Aristocrats For December 2025

ABT ADM ADP AFL ALB AMCR AOS


AbbVie Shares Rise To Intraday High After Key Trading Signal

Nov 12, 2025, 3:06 PM EST - 6 weeks ago

AbbVie Shares Rise To Intraday High After Key Trading Signal


AbbVie Has Many Bullish Attributes (Technical Analysis)

Nov 11, 2025, 10:40 PM EST - 7 weeks ago

AbbVie Has Many Bullish Attributes (Technical Analysis)


Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

Nov 8, 2025, 6:38 AM EST - 7 weeks ago

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

PFE


Best Dividend Aristocrats For November 2025

Nov 1, 2025, 10:25 AM EDT - 2 months ago

Best Dividend Aristocrats For November 2025

ABT ADM ADP AMCR AOS ATO BDX


AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

Oct 31, 2025, 3:56 PM EDT - 2 months ago

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript


AbbVie: Why Q3 Confirms Its Immunology Dominance

Oct 31, 2025, 10:39 AM EDT - 2 months ago

AbbVie: Why Q3 Confirms Its Immunology Dominance


AbbVie Lifts Profit Outlook as Sales Rise

Oct 31, 2025, 8:42 AM EDT - 2 months ago

AbbVie Lifts Profit Outlook as Sales Rise


AbbVie Reports Third-Quarter 2025 Financial Results

Oct 31, 2025, 7:49 AM EDT - 2 months ago

AbbVie Reports Third-Quarter 2025 Financial Results


Best Dividend Kings: October 2025

Oct 29, 2025, 5:11 AM EDT - 2 months ago

Best Dividend Kings: October 2025

ABM ABT ADM ADP AWR BDX BKH


AbbVie: Deep Discount Before Earnings

Oct 28, 2025, 11:28 AM EDT - 2 months ago

AbbVie: Deep Discount Before Earnings


Juhanialainen
Juhanialainen Dec. 31 at 10:02 AM
$SLS Hey $ABBV – let’s make it $80 per share and call it a day. Happy new year!
1 · Reply
1iquid
1iquid Dec. 31 at 7:15 AM
💎 Liquid® Live Actionable Trade Asset: $ABBV Contracts: $ABBV January 15, 2027 $230 Calls Scale in: $22.52- $27.52 Scale out: $87.56-$150.10 Profit Potential : 139% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 31 at 3:04 AM
Actionable Trade Alert for $ABBV: Market Context: $ABBV is currently trading at $229.74, showing strong momentum with an RSI of 64.54, indicating potential overbought conditions but still room for upward movement. The stock is above its 30-day MA of $227.95 and 50-day MA of $226.77, suggesting bullish sentiment. Directional Bias: The stock is trending upward, having recently approached its 60-day high of $239.29. This upward trajectory, combined with the RSI and moving averages, supports a bullish outlook. Trade Plan: - Suggested Entry: $230.00 - Stop Loss: $225.00 (risking $5.00) - Take Profit Targets: 1. $235.00 (Target 1: 2.17% ROI) 2. $240.00 (Target 2: 4.48% ROI) 3. $269.00 (Target 3: 17% ROI) This plan aims for a minimum of 17% ROI on the third target while maintaining a favorable risk-reward ratio. Monitor price action closely for adjustments. https://privateprofiteers.com
0 · Reply
GoodTidings
GoodTidings Dec. 30 at 11:38 PM
$SLS Can we say that ex Pfizer part of Sellas board puts $ABBV behind in case the BO war takes off... Is the time ticking for $ABBV or does board membership not have any influence on BO outcome?!!! 🤔🤔🤔
0 · Reply
rpc630
rpc630 Dec. 30 at 8:21 PM
$SLS $ABBV $BMY $RHHBY The Kennedy Woman probably was on this treatment. God rest her soul 🙏
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 30 at 8:16 PM
$SLS Daily Reminder: AZA+VEN the BAT - Best Available Treatment for SLS Phase 3 Control Arm Patients RECENTLY FAILED 3 Large Phase 3 Trials: VIALE-M FAILED in AML CR1 Maintenance VIALE-T FAILED in AML Post Stemcell Maintenance VERONA FAILED in MDS/AML Precursor - ALL FAILED DUE TO TOXicity Key Fact: $ABBV $BMY $RHHBY who own Azacitidine and Venetoclax - - these 3 Large A** Pharma, Know Right Now, Gps is wholly responsible for the Miraculous Survival of these Aml Second remission patients. They know precisely how their drugs perform - these are the 3 Likely to Be Bidding Now while SLS is Still Massively Undervalued. Ps. does everyone know, SLS a 14 FTE Drug Development co, eliminated the entire direct commercialization team in March of last year - ? the entire Pharma Industry Knows SLS is on the Block and the Clock is ticking.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 30 at 7:27 PM
$SLS $ABBV bought $IMGN for $10.1B based on ELAHERE achieving a MOS of 16.4 months for Platinum Resistant Ovarian Cancer Patients. - Gps + Keytruda $MRK Phase 2 Results are Better - 18.4 Months MOS in PR/OC. GPS + Keytruda achieved better MOS Results than than a drug bought for $10.1B. This is just One non-AML Market Comp for Gps - and worth 20x the Whole SLS market cap. Massive ROI Opportunity Investing in SLS right now, Opportunity of a Lifetime. https://www.fiercepharma.com/pharma/inside-abbvies-10b-immunogen-buyout-and-bidding-war-it-won
2 · Reply
Arunas1
Arunas1 Dec. 30 at 4:27 PM
Really nasty set ups right now $IWM $DIA $AMGN $ABBV $WING
0 · Reply
Arunas1
Arunas1 Dec. 30 at 4:12 PM
$ABBV & $AMGN
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 30 at 3:50 PM
$SLS Do the Math on the Total Addressable Market for Gps Immunotherapy and you will understand how true these words are. Gps will Set Records for patient uptake rates: 4x Survival Advantage - while maintaining near 100% QoL - No Toxicity, ease to administer, manufacture and Store, high margin, IP rights into 2035, FDA/ EU Orphan and Fast Track Designation, with Rare Pediatric Priority Review. An infinite Dosing Regime in the Maintenance setting, Years of COMPOUNDED REVENUE. 100,000 Patients in AML Remission Right Now +40,000 to 50,000 per year who'll be Eligible. Just in AML ... GPs in Combination with Keytruda $MRK Achieved Better Phase 2 Survival data (18.4MOS), than $IMGN Elahere (16.4MOS) Platinum Resistant End Stage ovarian cancer patients, $ABBV bought Elahere for $10.1B... Do the MATH... I've been here a while, sort through my posts.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 30 at 3:27 PM
$SLS Key Fact: $ABBV $BMY $RHHBY who own Azacitidine and Venetoclax - the BAT/ or Best Available Treatment for the SLS Phase 3 Control Arm Patients - these 3 Large A** Pharma, Know Right Now, Gps is wholly responsible for the Miraculous Survival of these Aml Second remission patients. They know precisely how their drugs perform - these are the 3 Likely to Be Bidding Now while SLS is Still Massively Undervalued. Ps. does everyone know, SLS a 14 FTE Drug Development co, eliminated the entire direct commercialization team in March of last year - ? the entire Pharma Industry Knows SLS is on the Block and the Clock is ticking.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 30 at 3:23 PM
$SLS for those who may not Know, While we are seeing Miraculous ALL POOLED OS Data from the SLS Regal Trial - Aza+VEN, the BAT - Best Available Treatment for Control Arm Patients, Recently FAILED 3 Large Phase 3 Trials Sponsored by $ABBV $BMY $RHHBY - AzaVEN Failed the VIALE-M Phase 3 Maintenance Trial for CR1 patients and Failed the VIALE-T P3 Maintenance Trial for Post Transplant AML patients and also Failed the VERONA MDS/Aml Precursor P3 AND in the VIALE-A Trial* 83% of Aza VEN Patient Suffered Serious Adverse Events and 23% DIED from TAKING Aza+VEN. Aza+VEN is the Best Available Treatment (BAT) for the SLS REGAL Phase 3 Control Arm Patients - and it is deadly. Writing is on the Wall - its GPS, Gps Immunotherapy is the reason patients are Surviving - 3 Dr's who treat the actual Patients are on Record, Telling everyone, GPs is doing what its done in all previous trials, Preventing Relapse and Extending Survival - including 4 Phase 2 Trials.
0 · Reply
MichaelOwen192
MichaelOwen192 Dec. 30 at 3:04 PM
$ASML $ABBV $BAC $COST $AMD Productivity, dividends, and chips powering portfolios https://howardlindzonanalysis.beehiiv.com/p/the-next-big-market-wave-is-forming-be-early-not-late
0 · Reply
dogDazeSummer
dogDazeSummer Dec. 30 at 1:28 PM
$IFRX algos read news like a mixed data set. but we all know it was already dead (vs algos seeing mixed), so agree it’s a net positive. It’s a $900M potential - so simple question: is it worth it for $RHHBY $ABBV $PFE $AMGN to spend x $ to file NDA ? As a pipeline company, Inflarx doesn’t have funds to take drugs to market / distribute/ market. Lessons learned w Gohibic / Covid. The way analysts value is probably of success x $ revenue (POS). So it will be interesting to see how they view. This also strengthens the MOA / clears up concerns raised and helps support izicopan MOA & data
2 · Reply
EliteStockTrader
EliteStockTrader Dec. 30 at 1:15 PM
$ABBV Current Price & Change: $230.84 (+0.37%) Trend Indicator: Bullish RSI Level: 67.4 Volume Activity: -28.6% vs avg Volatility: 1.12% Price Target: $229.38 Confidence: 85% I do not provide personalized financial advice or sell premium subscriptions. Any communication requesting payment for services is unauthorized. My only official outlet is https://stocksecret.news Always conduct your own due diligence.
0 · Reply
ZenithTrades
ZenithTrades Dec. 30 at 11:42 AM
0 · Reply
Longbuy1
Longbuy1 Dec. 30 at 4:00 AM
$SLS Blows my mind that shorts are going to try to continue to attack this. 217M float, market cap is 600M. GPSs by itself is worth a floor of 10 billion, that's 45$ a share. Then factor in SLS 009 whose trial also exceeded expectations; the potential drug cocktail SLS 009 combined with GPS regal. Orphan drug treatments make a ton of money (look up Fabrazyme and its history). They have 75M in cash and average a burn of 7M a quarter, 13 employees. Biotech is hot, and immunotherapies are even hotter, than put cancer treatment with no toxic profile into that mix. (BAT is toxic as hell) You're out of your fucking mind to short this. Plus 26% tute ownership, Black Rock being one of the top dogs. Out of all the crap on the market to short, your going to pick this? Hold it through 2026, save on your capital gains. Your shares are going to be converted into $PFE $MRK $ABBV or another big pharma player. This shits going to blow up.
4 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 29 at 9:21 PM
Enter: $ABBV Calls Strike Price: $230 Expiry Date: JAN 23 2026 Buy in Price: $5.30 - $5.90 Sell Price: $9.80 Profit : +85% (Turn every $1 into $1.85) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 29 at 8:54 PM
$SLS for those who may not Know, While we are seeing Miraculous ALL POOLED OS Data from the SLS Regal Trial - Aza+VEN, the BAT - Best Available Treatment for Control Arm Patients, Recently FAILED 3 Large Phase 3 Trials Sponsored by $ABBV $BMY $RHHBY - AzaVEN Failed the VIALE-M Phase 3 Maintenance Trial for CR1 patients and Failed the VIALE-T P3 Maintenance Trial for Post Transplant AML patients and also Failed the VERONA MDS/Aml Precursor P3 AND in the VIALE-A Trial* 83% of Aza VEN Patient Suffered Serious Adverse Events and 23% DIED from TAKING Aza+VEN. Aza+VEN is the Best Available Treatment (BAT) for the SLS REGAL Phase 3 Control Arm Patients - and it is deadly. Writing is on the Wall - its GPS, Gps Immunotherapy is the reason patients are Surviving - 3 Dr's who treat the actual Patients are on Record, Telling everyone, GPs is doing what its done in all previous trials, Preventing Relapse and Extending Survival - including 4 Phase 2 Trials.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 29 at 5:28 PM
$SLS Smart Long Money Moving into Position. Investment Opportunity of a Lifetime - Share Price will double a couple times. A positive Gps Phase 3 Result is worth $30 to $40B to Big Pharma. Gps will Set records for patient uptake rates; 4x-5x OS Benefit - while maintaining near 100% QoL Little to No Side Effects - Easy to Administer, Manufacture and Store, FDA/Eu Orphan Designation / Eu/FDA Fast Track + Rare Pediatric Priority Review Designation, IP rights into 2037 - $9B TAM just for GPS in AML - is worth Close to $40B to Big Pharma. - Gps Immunotherapy is a Platform Agent, and achieved Better Combination $MRK Phase 2 MOS results in Plat Resistant Ovarian Cancer - than Elehare which $ABBV bought for 10.1B. - and then add in 009 / the first ever safe CDKinase 9 Inhibitor - achieved Better MOS data than Magrolimab which was bought for $4.9B $GILD based on P1 DATA.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 29 at 4:41 PM
$SLS $ABVX Don't Forget - BAT -for Control Patients Aza+VEN Recently Failed 3 Large $ABBV $BMY $RHHBY Sponsored Phase 3 Trials due to Toxicity. the VERONA MDS/AML Precursor Trial Failed AzaVEN VIALE-M a Phase 3 Maintenance Trial for AML CR1 Patients Aza+VEN VIALE-T a Phase 3 Maintenance Trial Post Stem Cell Transplant Patients Failed
0 · Reply
Longbuy1
Longbuy1 Dec. 29 at 4:36 PM
$SLS BO offers will start at 10billion that's the floor, 217M float with all warrants exercised factor in. That's 45$ a share in 2026. Bidding war between $PFE $MRK $ABBV they all want immunotherapies to treat cancer and GPS is turning into a lifelong treatmemt, for a dancer that life expectancy for 6-8 months.
1 · Reply